Cargando…
Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System
With our increasing appreciation of the true complexity of diseases and pathophysiologies, it is clear that this knowledge needs to inform the future development of pharmacotherapeutics. For many disorders, the disease mechanism itself is a complex process spanning multiple signaling networks, tissu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150252/ https://www.ncbi.nlm.nih.gov/pubmed/25225492 http://dx.doi.org/10.3389/fendo.2014.00142 |
_version_ | 1782332869056659456 |
---|---|
author | Janssens, Jonathan Etienne, Harmonie Idriss, Sherif Azmi, Abdelkrim Martin, Bronwen Maudsley, Stuart |
author_facet | Janssens, Jonathan Etienne, Harmonie Idriss, Sherif Azmi, Abdelkrim Martin, Bronwen Maudsley, Stuart |
author_sort | Janssens, Jonathan |
collection | PubMed |
description | With our increasing appreciation of the true complexity of diseases and pathophysiologies, it is clear that this knowledge needs to inform the future development of pharmacotherapeutics. For many disorders, the disease mechanism itself is a complex process spanning multiple signaling networks, tissues, and organ systems. Identifying the precise nature and locations of the pathophysiology is crucial for the creation of systemically effective drugs. Diseases once considered constrained to a limited range of organ systems, e.g., central neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’ disease (HD), the role of multiple central and peripheral organ systems in the etiology of such diseases is now widely accepted. With this knowledge, it is increasingly clear that these seemingly distinct neurodegenerative disorders (AD, PD, and HD) possess multiple pathophysiological similarities thereby demonstrating an inter-related continuum of disease-related molecular alterations. With this systems-level appreciation of neurodegenerative diseases, it is now imperative to consider that pharmacotherapeutics should be developed specifically to address the systemic imbalances that create the disorders. Identification of potential systems-level signaling axes may facilitate the generation of therapeutic agents with synergistic remedial activity across multiple tissues, organ systems, and even diseases. Here, we discuss the potentially therapeutic systems-level interaction of the glucagon-like peptide 1 (GLP-1) ligand–receptor axis with multiple aspects of the AD, PD, and HD neurodegenerative continuum. |
format | Online Article Text |
id | pubmed-4150252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-41502522014-09-15 Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System Janssens, Jonathan Etienne, Harmonie Idriss, Sherif Azmi, Abdelkrim Martin, Bronwen Maudsley, Stuart Front Endocrinol (Lausanne) Endocrinology With our increasing appreciation of the true complexity of diseases and pathophysiologies, it is clear that this knowledge needs to inform the future development of pharmacotherapeutics. For many disorders, the disease mechanism itself is a complex process spanning multiple signaling networks, tissues, and organ systems. Identifying the precise nature and locations of the pathophysiology is crucial for the creation of systemically effective drugs. Diseases once considered constrained to a limited range of organ systems, e.g., central neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’ disease (HD), the role of multiple central and peripheral organ systems in the etiology of such diseases is now widely accepted. With this knowledge, it is increasingly clear that these seemingly distinct neurodegenerative disorders (AD, PD, and HD) possess multiple pathophysiological similarities thereby demonstrating an inter-related continuum of disease-related molecular alterations. With this systems-level appreciation of neurodegenerative diseases, it is now imperative to consider that pharmacotherapeutics should be developed specifically to address the systemic imbalances that create the disorders. Identification of potential systems-level signaling axes may facilitate the generation of therapeutic agents with synergistic remedial activity across multiple tissues, organ systems, and even diseases. Here, we discuss the potentially therapeutic systems-level interaction of the glucagon-like peptide 1 (GLP-1) ligand–receptor axis with multiple aspects of the AD, PD, and HD neurodegenerative continuum. Frontiers Media S.A. 2014-09-01 /pmc/articles/PMC4150252/ /pubmed/25225492 http://dx.doi.org/10.3389/fendo.2014.00142 Text en Copyright © 2014 Janssens, Etienne, Idriss, Azmi, Martin and Maudsley. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Janssens, Jonathan Etienne, Harmonie Idriss, Sherif Azmi, Abdelkrim Martin, Bronwen Maudsley, Stuart Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System |
title | Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System |
title_full | Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System |
title_fullStr | Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System |
title_full_unstemmed | Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System |
title_short | Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System |
title_sort | systems-level g protein-coupled receptor therapy across a neurodegenerative continuum by the glp-1 receptor system |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150252/ https://www.ncbi.nlm.nih.gov/pubmed/25225492 http://dx.doi.org/10.3389/fendo.2014.00142 |
work_keys_str_mv | AT janssensjonathan systemslevelgproteincoupledreceptortherapyacrossaneurodegenerativecontinuumbytheglp1receptorsystem AT etienneharmonie systemslevelgproteincoupledreceptortherapyacrossaneurodegenerativecontinuumbytheglp1receptorsystem AT idrisssherif systemslevelgproteincoupledreceptortherapyacrossaneurodegenerativecontinuumbytheglp1receptorsystem AT azmiabdelkrim systemslevelgproteincoupledreceptortherapyacrossaneurodegenerativecontinuumbytheglp1receptorsystem AT martinbronwen systemslevelgproteincoupledreceptortherapyacrossaneurodegenerativecontinuumbytheglp1receptorsystem AT maudsleystuart systemslevelgproteincoupledreceptortherapyacrossaneurodegenerativecontinuumbytheglp1receptorsystem |